Hyperparathyroidism Market to Reach USD 3.76 Billion by 2034

Pune, India - December 2025 - The global Hyperparathyroidism Market, valued at USD 2.24 billion in 2024, is projected to reach USD 3.76 billion by 2034, growing at a 5.2% CAGR (2025-2034), according to Exactitude Consultancy. Rising CKD-associated secondary hyperparathyroidism, improved imaging diagnostics, and strong uptake of calcimimetics are key factors driving market growth.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71994

Market Summary
The Hyperparathyroidism Market is expanding steadily as the condition-characterized by excess parathyroid hormone (PTH) secretion-becomes more widely diagnosed across primary, secondary, and tertiary forms.
• Primary Hyperparathyroidism arises from a parathyroid adenoma or hyperplasia.
• Secondary Hyperparathyroidism is commonly associated with chronic kidney disease (CKD), vitamin D deficiency, or malabsorption.
• Tertiary Hyperparathyroidism develops after prolonged SHPT, especially in dialysis patients.
Diagnosis relies on serum calcium, PTH levels, phosphorus levels, 24-hour urinary calcium, and imaging tools such as ultrasound, sestamibi scans, CT/MRI, and emerging PET tracers.

Treatment options vary by disease type. Minimally invasive parathyroidectomy (MIP) is the standard for primary hyperparathyroidism, while pharmacological therapies such as calcimimetics (cinacalcet, etelcalcetide), vitamin D analogs, phosphate binders, and bisphosphonates dominate secondary hyperparathyroidism management. Innovations in CKD care and surgical navigation systems are improving treatment outcomes.

North America leads due to high CKD prevalence and strong treatment access, while Asia-Pacific is the fastest-growing region, driven by rising kidney disease, vitamin D deficiency, and improved diagnostic pathways.

Key Takeaways
• 2024 Market Size: USD 2.24 Billion
• 2034 Forecast: USD 3.76 Billion
• CAGR: 5.2% (2025-2034)**
• Cinacalcet & etelcalcetide remain leading calcimimetic therapies
• Minimally invasive parathyroid surgery adoption growing globally
• CKD-driven SHPT significantly expanding the patient pool

Market Drivers
• Rising burden of chronic kidney disease worldwide
• Increase in vitamin D deficiency and metabolic bone disorders
• Advancements in parathyroid imaging and intraoperative localization
• Growing use of calcimimetic and vitamin D analog therapies
• Improved awareness and diagnostic screening for calcium disorders

Segmentation Snapshot
By Disease Type
• Primary Hyperparathyroidism
• Secondary Hyperparathyroidism (CKD-driven) - Largest Segment
• Tertiary Hyperparathyroidism

By Treatment Type
• Surgical Treatment
o Minimally Invasive Parathyroidectomy (MIP)
o Bilateral Neck Exploration
• Pharmacological Treatment
o Calcimimetics (Cinacalcet, Etelcalcetide)
o Vitamin D Analogs (Calcitriol, Paricalcitol)
o Phosphate Binders
o Bisphosphonates
o Emerging PTH-regulating therapies

By Diagnostic Method
• Serum Calcium & PTH Testing
• Phosphorus Testing
• 24-Hour Urinary Calcium Measurement
• Parathyroid Ultrasound
• Sestamibi Scan
• CT/MRI & PET Imaging
By End User
• Hospitals
• Endocrinology Clinics
• Dialysis Centers
• Diagnostic Laboratories
• Research Institutions

By Region
• North America (Largest Market)
• Europe
• Asia-Pacific (Fastest Growing Region)
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/71994/hyperparathyroidism-market

Recent Developments
• Improved surgical navigation tools enhancing MIP success rates.
• Growth of etelcalcetide usage in dialysis-based SHPT management.
• AI-enabled detection models improving calcium disorder screening.
• Pipeline development of next-generation calcimimetics and PTH modulators.

Expert Quote - Irfan Tamboli, Business Development Executive
"Hyperparathyroidism management is evolving quickly with minimally invasive surgery and targeted calcimimetic therapies driving better outcomes for CKD and primary disease patients alike."

Conclusion
The Hyperparathyroidism Market will continue expanding through 2034 as CKD prevalence rises, diagnostic imaging improves, and adoption of calcimimetic therapies increases worldwide. Companies innovating in endocrine surgery technologies, renal metabolism therapeutics, and advanced calcium management solutions will lead future growth.

This report is also available in the following languages : Japanese (副甲状腺機能亢進症市場), Korean (부갑상선기능항진증 시장), Chinese (甲状旁腺功能亢进症市场), French (Marché de l'hyperparathyroïdie), German (Markt für Hyperparathyreoidismus), and Italian (Mercato dell'iperparatiroidismo), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71994

Related Reports

Secondary Hyperparathyroidism Market
https://exactitudeconsultancy.com/reports/72046/secondary-hyperparathyroidism-market

Parathyroid Disorders Market
https://exactitudeconsultancy.com/reports/51969/parathyroid-disorders-market

Calcimimetic Market
https://exactitudeconsultancy.com/reports/59360/global-calcimimetic-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.